Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery
Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: KYUNG WON SHIN
- Phone Number: 02-2072-2469
- Email: skwskw126@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Adults aged 19 years or older scheduled to undergo nasal surgery requiring general anesthesia
Exclusion Criteria
- Declines or is unable to provide informed consent
- Body mass index (BMI) ≥ 30 kg/m²
- Pre-existing neurological or cognitive impairment
- Known contraindication or allergy to remimazolam, propofol, or flumazenil
- Any condition judged by the investigator to make participation inappropriate (e.g., unstable medical status, severe comorbidities)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Remimazolam
Participants receive general anesthesia induced and maintained with remimazolam-based total intravenous anesthesia.
At the end of surgery, flumazenil (0.2-1.0 mg) is administered to reverse the sedative effect.
|
General anesthesia is induced and maintained with remimazolam (initial infusion approximately 6 mg/kg/hr for induction, then 1-2 mg/kg/hr for maintenance), along with remifentanil for analgesia.
At the end of surgery, flumazenil is administered to reverse the sedative effect, starting with 0.2 mg IV, followed by 0.1 mg incremental doses every 1 minute as needed, up to a total dose of 1.0 mg.
|
|
Active Comparator: Propofol
Participants receive general anesthesia induced and maintained with propofol.
|
General anesthesia is induced and maintained with propofol using target-controlled infusion (effect-site concentration up to 4.0 μg/mL), along with remifentanil for analgesia.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Emergence Agitation
Time Frame: From discontinuation of anesthesia to exit in the operating room
|
From discontinuation of anesthesia to exit in the operating room
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Tracheal Extubation
Time Frame: From anesthesia discontinuation to extubation in the operating room
|
From anesthesia discontinuation to extubation in the operating room
|
|
|
Intraoperative Hemodynamic Stability
Time Frame: During anesthesia
|
During anesthesia
|
|
|
Incidence of Airway Complications During Emergence
Time Frame: during anesthesia
|
Complications such as coughing, desaturation, and laryngospasm will be recorded based on direct observation by anesthesiologists.
|
during anesthesia
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Mental Disorders
- Postoperative Complications
- Pathologic Processes
- Confusion
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Delirium
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Emergence Delirium
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Phenols
- Benzene Derivatives
- Benzazepines
- Benzodiazepines
- Benzodiazepinones
- Propofol
- Flumazenil
- remimazolam
Other Study ID Numbers
Other Study ID Numbers
- 2507-174-1661
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.